<DOC>
	<DOC>NCT03072641</DOC>
	<brief_summary>The purpose of the study is to determine if probiotic bacteria have a beneficial effect on the colon cancer-associated microbiota and epigenetic alterations in colon cancer. Dietary supplementation consists of two ProBion Clinica tablets, yielding a daily dose of 1.4 x 10 ˄ 10 Bifidobacterium lactis Bl-04 (ATCC SD5219), 7x10 ˄ 9 Lactobacillus acidophilus NCFM (ATCC 700396), and 0.63 g inulin.</brief_summary>
	<brief_title>Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>At least one malignant tumor in the colon Study subjects with adenomas, or who received recent antibiotic therapy or consumed probiotics regularly were excluded.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Probiotics</keyword>
	<keyword>Epigenetics</keyword>
	<keyword>Microbiota</keyword>
</DOC>